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Key points:
1) Consider sarcoidosis in patients presenting with acute onset neuropathic pain.
2) Specialized imaging/, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, 
Alberta, Canadaautonomic testing with biopsy is required to confirm sarcoidosis.
3) Corticosteroids and immunomodulators may improve patient outcomes.
Abstract
Sarcoidosis is characterized by multisystem granulomatous formation particularly in the chest. 
In this case report, we present an uncommon case highlighting significant peripheral nerve 
involvement, a phenomenon that is not well recognized in sarcoidosis. The patient presented 
with severe incapacitating pain. Sarcoidosis as being the underlying cause was only 
established after extensive investigations. This case highlights the importance of recognizing 
small fibre peripheral polyneuropathy as a possible presentation of sarcoidosis. This could help 
to direct appropriate medical intervention.
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1. Introduction
    Granulomas lesions in sarcoidosis can affect 
many organs including lungs, eyes, kidneys, 
heart and the nervous system (O'Regan and 
Berman 2012). However, it most commonly 
presents with lung and skin involvement. In 
contrast, peripheral nerve involvement in 
sarcoidosis is much less common (Galassi et 
al. 1984). This report describes an unusual 
case with severe subacute incapacitating 
neuropathic pain. The underlying etiology was 
only revealed after extensive investigations. 
This case highlights the importance of being 
vigilant about the possibility of polyneuropathy 
with predominantly small fibre involvement due 
to sarcoidosis as it could have important 
management implications.
2.2 Additional examinations and 
workup
2. Case report
     A 57-year-old, obese, construction worker of 
Western European origin presented with a two-
week history of symmetric pain in his limbs, 
worse in the legs. He described it as a burning 
sensation affecting the foot to the mid-thigh and 
from the hand to the elbow. Over the ensuing 
two months, the pain progressed to the extent 
that it severely hampered his daily activities 
and disrupted his sleep. The patient denied 
having any constitutional symptoms such as 
fever, chills, or night sweats. Strength was not 
affected despite discomfort when trying to 
move. He denied changes in vision, 
swallowing, speech or bowel and bladder 
control. Systemic enquiry was negative for 
cardiac or respiratory symptoms. A 60-pound 
weight loss over the prior months was 
identified. The patient attributed this to a calorie 
restricted low carbohydrate diet that he had 
been on for 6 months. At the time of 
presentation, he remained over 200 pounds. 
Except for gout, nephrolithiasis, and remote 
facial melanoma, his past medical history was 
unremarkable. The melanoma was diagnosed 
over 10 years ago and was treated with wide 
margin excision with no sign of recurrence. He 
was a non-smoker and denied use of alcohol or 
illicit substances. The patient had no known 
medication allergies, history of recent foreign  
2.1 Initial patient presentation
    On neurological examination, the patient was 
allodynic to light touch, especially in distal 
limbs. Pinprick, temperature and vibration 
sensations were decreased in a glove-stocking 
distribution. Strength testing was unremarkable 
with normal stretch reflexes and no pathologic 
reflexes. Cranial nerve examination was 
normal. Romberg sign was mildly positive due 
to proprioceptive loss, but finger-nose test and 
heel-shin test were normal. Quantitative 
sudomotor axon reflex test (QSART), 
quantitative sensory testing (QST), and cold 
perception threshold testing (CPT) were 
unremarkable. However, the heart rate 
variability test revealed diminished response to 
deep breathing, Valsalva maneuver indicative 
of autonomic dysfunction.
	    With the poorly controlled unrelenting pain, 
he was admitted to hospital for symptom 
management and further investigations. He was 
put on high doses of analgesics including 
hydromorphone, pregabalin, and duloxetine. 
Aside from mildly elevated liver enzymes and 
iron deficiency, hematologic investigations were 
largely unremarkable. Further investigations 
including complete blood count, hemoglobin 
a1c, glucose tolerance, nutritional deficiency 
(i.e., serum albumin, vitamins B1, B6, B12 and 
E), virus panel (HIV, Hepatitis B and C, 
Parvovirus B19 and EBV), immune profile (i.e., 
ANA, ENA, ANCA, dsDNA, CRP, RF, C3/C4, 
anti-transglutaminase), and a workup for 
paraproteinemia (i.e., SPEP, free kappa/lambda 
fractions) were all negative. Skin, ophthalmic, 
and back examinations were unremarkable. No 
tuberculosis or other infections were found. 
Chest x-rays only demonstrated mild pleural 
thickening. Computerized tomography (CT) 
imaging of the abdomen and magnetic 
resonance imaging (MRI) of the brain and spine 
were unremarkable. However, cerebrospinal 
fluid (CSF) analysis revealed albuminocytologic 
dissociation with elevated protein. Because of 
the suspicion of an inflammatory 
polyneuropathy, he was given a 5-day course 
travel and had no autoimmune or 
granulomatous infections. There are no 
malignancies or autoimmune diseases in his 
family history.
Senger  et al.,  2019
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of intravenous immunoglobulin (IVIG) but with 
no benefit.
  The patient was then referred for 
electrodiagnostic studies. Nerve conduction 
studies confirmed a mild bilateral length 
dependent sensory axonopathy in the upper 
and lower extremities (Table 1). While his 
symptoms were suggestive of small sensory 
nerve fibre involvement, these findings 
suggested that large diameter myelinated 
sensory nerve fibres were also mildly affected. 
Based on these findings and the clinical 
presentation, further workup was done for 
paraneoplastic syndrome (i.e., anti-Hu/Yo and 
Ri) but the results were negative. Taking the 
subtle chest x-rays changes into account, a 
workup for sarcoidosis was started. These 
included anti-amphiphysin, anti-Ma2 and anti-
CV2 and angiotensin-converting enzyme (ACE) 
levels that turned out to be normal. However, 
CT of the chest revealed mediastinal lymph 
node enlargement. He reported no foreign 
travel and had no autoimmune or 
granulomatous infections.
      There were no malignancies or 
autoimmune diseases in his family history. A 
whole-body positron emission tomography 
(PET)/CT scan was therefore ordered. It 
2.3 Electrodiagnostic studies and 
PET/CT scan confirm sarcoidosis
confirmed perihilar and mediastinal 
lymphadenopathy with increased radioisotope 
uptake (Figure 1a). Lymph node biopsy 
provided histological evidence of non-
necrotizing granulomas consistent with 
sarcoidosis (Figure 1b). The presence of small 
nerve fibre neuropathy was further supported 
by abnormalities on autonomic testing and 
reduced intraepidermal nerve fibre density on 
punch skin biopsy. Sural nerve biopsy 
confirmed marked axonal loss (Figure 1c and 
d) with no granuloma. Based on these findings, 
the patient was started on high dose 
prednisone and methotrexate. His pain showed 
substantial improvement after a week of 
treatment, he was then discharged home. 
Following gradual tapering of prednisone, the 
patient remained stable with no recurring 
symptoms. Therefore, no further follow up x-
rays or electro-conductive studies were done 
within the follow up window.
Table1.Specialized Neuropathy Investigations 
     Sarcoidosis is a granulomatous disorder that 
affects multiple organ systems. With most 
common onset in the third to fourth decade of 
life, it has an incidence of 35.5/100,000 in 
African Americans, which is much higher than 
in Caucasians (10.9/100,000). By far the most 
frequently affected organs are lungs (>90%), 
Senger et al.,  2009
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heart (25-50%), eyes (25%), and skin (30%) 
(Iannuzzi and Fontana 2011; Lower and Weiss 
2008). Although neurosarcoidosis occurs in 
around 5% of patients, it frequently involves the 
central nervous system including cranial 
neuropathy, pituitary/hypothalamic dysfunction, 
psychiatric symptoms, hydrocephalus and 
meningitis. In contrast, involvement of the 
peripheral nervous system is much rarer. The 
patient in this case study presented with no 
symptoms of granulomas in the most frequently 
affected organs, and only after biopsy of lymph 
nodes granulomas were found. Typical central 
nervous system involvement is expected, 
however, the lack of thoracic lesions indicated 
the presence of peripheral small fibre 
neuropathy instead. Tthis demonstrates the 
significance of the study.
   A review of 57 patients with sarcoidosis-
associated peripheral neuropathy reported 
polyradiculoneuropathy (39%), polyneuropathy 
(33%) and mononeuropathy (10%) (Burns et al. 
2006). Even less known is the involvement of 
small and poor myelinated or unmyelinated 
3.1 Other causes of small fibre 
neuropathy
   The differential diagnosis of small fibre 
neuropathy is wide (Themistocleous et al. 
2014). In contrast to sarcoidosis, there are 
other far more common causes. These include 
diabetes, alcohol toxicity, nutritional deficiency, 
malignancy, infection and drug toxicity (Hoitsma 
et al. 2004) (Table 2). A feature that they have 
in common is upregulation of pro-inflammatory 
cytokines (TNF-α, IL-1) that act as mediators of 
neuropathic pain. 
nerve fibres, making the accurate diagnosis of 
neurosarcoidosis challenging.
    Electrodiagnostic studies are often non-
informative as they only assess large 
myelinated nerve fibres (Hoitsma et al. 2002). 
Furthermore, there is currently no “gold 
standard” diagnostic test for small fibre 
neuropathy. Therefore, multiple tests to 
evaluate the somatic and autonomic fibre 
systems are necessary. These include 
quantitative sensory testing (QST), cold 
perception threshold testing (CPT), and 
sympathetic skin response (SSR). In addition, 
skin biopsy may be helpful (Hoitsma et al. 
2004). Immunofluorescence staining with 
PGP-9.5 of the skin allows intraepidermal nerve 
fibre density (IENFD) to be determined. 
Although it has high specificity (977%), the 
sensitivity is low (69%) (Hoitsma et al. 2004).
3.2 Management
  The most troublesome of small fibre 
neuropathy are positive symptoms including 
allodynia, burning, lancinating and thermal 
hyperalgesia. Patients may additionally 
complain of myalgia, particularly cramping of 
the calf muscles, and/or restless leg syndrome.   
	  Symptom management of small fibre 
neuropathy is challenging, with only 30-50% of 
patients benefiting from traditional therapies 
(Finnerup et al. 2015). Even in those 
individuals, the pain scores usually only 
improve by 30-50%. Frequently used 
medications include anticonvulsants, 
antidepressants, opioids and topical capsaicin/
lidocaine. Many of these cause significant side
Figure 1. a) PET/CT scan of the chest showing 
increased radioisotope uptake in the 
mediastinum. b) Lymph node biopsy revealed 
non-caseating granulomas supportive of a 
diagnosis of sarcoidosis. c) Hematoxylin and 
eosin stain of sural nerve biopsy. At low 
magnification (100x), two fascicles showing 
axon loss. d) At higher magnification (1000x), 
toluidine blue-stained semithin section of sural 
nerve biopsy confirmed marked reduction of 
myelinated fibers. Arrows: 'myelin ovoids' (sign 
of axonal damage). Asterisks:  phagocytosing 
macrophages.
Senger et al.,  2019
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   There remains a paucity of information 
regarding long-term outcomes for patients with 
sarcoidosis-associated small fibre neuropathy. 
Reports suggest that typical symptoms of small 
fibre neuropathy worsen within the first weeks to 
months before plateauing. After that, patients 
demonstrate variable degrees of improvement.  
effects. Therefore, definitive management of 
the underlying sarcoidosis is critical, as rapid 
initiation of treatment has been shown to be a 
prognostic feature for pain improvement (Burns 
et al. 2006).   	Sarcoidosis is best treated with 
steroids and steroid sparing agents 
(methotrexate, azathioprine, cyclosporin), with 
medications such as anti-cytokines, 
antimalarials, and monoclonal antibodies 
reserved for chronic resistance (Heij et al. 
2012). Immune-modulating therapies such as 
intravenous gamma globulin (IVIG) have also 
shown efficacy in alleviating symptoms 
(Parambil et al. 2011). ARA290 is a new drug 
that has been shown promising effects in the 
treatment of neurosarcoidosis. By mimicking 
erythropoietin, it acts on the innate repair 
receptor to trigger anti-inflammatory and anti-
apoptotic processes that limit injury and 
promote repair.It has been shown to improve 
pain, neuropathic symptoms, quality of life and 
exercise capacity (Heij 2016).
3.3 Outcomes
     Given the heterogeneity of clinical signs and 
symptoms, and negative electrodiagnostic 
studies, small fibre neuropathy is a rare 
presentation of sarcoidosis that is challenging to 
recognize. Although we were able to establish 
the presence of a small fibre polyneuropathy 
through tests including QST, CPT, CHEPT, 
SSR, skin biopsies and nerve conduction 
studies, the underlying cause was only 
established following a PET/CT scan. This is a 
valuable test that when combined with a high 
index of clinical suspicion enable clinicians to 
make an accurate early diagnosis. Timely 
recognition is critical for patient management, 
as early medical intervention portends better 
outcomes. 
4. Conclusion
The author is thankful of the anonymous reviewers whose 
valuable comments help in refined and improved the 
manuscript. The authors declare no competing interests; 
this case report received no external funding. 
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